Holen Sie sich die Stockscreener-App
2.38
1.65%
-0.04
Handel nachbörslich:
2.38
Schlusskurs vom Vortag:
$2.42
Offen:
$2.488
24-Stunden-Volumen:
1.08M
Relative Volume:
0.77
Marktkapitalisierung:
$675.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-2.9024
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
-0.42%
1M Leistung:
-1.65%
6M Leistung:
+50.63%
1J Leistung:
-12.50%
1-Tages-Spanne:
$2.28
$2.488
1-Wochen-Bereich:
$2.28
$2.54
52-Wochen-Spanne:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.38 | 686.48M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Using fundamentals and technicals on Erasca Inc.July 2025 News Drivers & Risk Adjusted Swing Trade Ideas - newser.com
Is Erasca Inc. stock affected by interest rate hikes2025 Historical Comparison & AI Driven Stock Movement Reports - newser.com
Why Erasca Inc. stock could see breakout soonJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - newser.com
Can Erasca Inc. stock deliver sustainable ROEJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Analyzing drawdowns of Erasca Inc. with statistical toolsEarnings Miss & Weekly High Conviction Trade Ideas - newser.com
Full technical analysis of Erasca Inc. stockEntry Point & Free Verified High Yield Trade Plans - newser.com
How to forecast Erasca Inc. trends using time seriesJuly 2025 Update & Safe Entry Point Alerts - newser.com
Best data tools to analyze Erasca Inc. stock2025 Market Overview & Fast Gain Swing Alerts - newser.com
Why Erasca Inc. stock remains a top recommendationMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
Is Erasca Inc. stock oversold or undervaluedQuarterly Profit Summary & Weekly High Conviction Ideas - newser.com
How Erasca Inc. stock performs in weak economyTrade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Risk vs reward if holding onto Erasca Inc.July 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Heatmap analysis for Erasca Inc. and competitorsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Understanding Erasca Inc.’s price movementWatch List & Stepwise Trade Signal Guides - newser.com
Is Erasca Inc. still worth holding after the dipJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Is Erasca Inc. stock poised for growthEarnings Growth Summary & Entry and Exit Point Strategies - newser.com
Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study - TipRanks
Will Erasca Inc. stock maintain growth storyGold Moves & Long-Term Growth Portfolio Plans - newser.com
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):